Chronic hepatitis C: Future treatment

Clinical Pharmacology: Advances and Applications

Volumn 6, Issue 1, 2014, Pages

  Wendt, Astrid ^a   Adhoute, Xavier ^a   Castellani, Paul ^a   Oules, Valerie ^a   Ansaldi, Christelle ^a   Benali, Souad ^a   Bourlière, Marc ^a  

^a HÔPITAL SAINT JOSEPH   (France)

Author keywords

Cirrhosis; Direct antiviral agents; Host targeting agents; Interferon free regimen; Pange notypic activity; SVR

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DIRECT ANTIVIRAL AGENT; NONNUCLEOTIDE INHIBITOR; NS5A COMPLEX INHIBITOR; NS5B NUCLEOSIDE NUCLEOTIDE INHIBITOR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; LIVER CIRRHOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

EID: 84892151143     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S30338     Document Type: Article

References (111)

1. Lauer GM, Walker BD. Hepatitis C Virus Infection. N Engl J Med. 2001;345:41-52.
2. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-1206.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416.
4. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014-1024.
5. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13): 1207-1217.
6. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417-2428.
7. Wartelle-Bladou C, Le Folgoc G, Bourliere M, Lecomte L. Hepatitis C therapy in non-genotype 1 patients: the near future. J Viral Hepat. 2012;19(8):525-536.
8. Cacoub P, Bourliere M, Lubbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol. 2012;56(2):455-463.
9. Sulkowski MS, Roberts S, Afdhal NH, et al. Ribavirin dose modifcation in treatment-naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies [abstract]. J Hepatol. 2012;56(Suppl 2): S459-S460.
10. Poordad F, Lawitz E, Reddy KR, et al. Timing and magnitude of ribavirin dose reduction do not impact sustained virologic response rates with boceprevir + peginterferon alfa-2b/ribavirin in the anemia management study in chronic HCV genotype 1 patients [abstract]. Hepatology. 2012;56(Suppl S1):269A-270A.
11. Lawitz E, Zeuzem S, Nyberg LM, Nelson DR, Rossaro L, Balart LA, et al. Boceprevir combined with peginterferon alfa-2b/ribavirin in treatment-naive chronic HCV genotype 1 patients with compensated cirrhosis: sustained virologic response and safety subanalyses from the anemia management study [abstract]. Hepatology. 2012; 56(Suppl):216A.
12. Ciesek S, von Hahn T, Manns MP. Second-wave protease inhibitors: choosing an heir. Clin Liver Dis. 2011;15(3):597-609.
13. Fusco DN, Chung RT. New protease inhibitors for HCV - help is on the way. J Hepatol. 2011;54(6):1087-1089.
14. Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int. 2011;31(Suppl 1):68-77.
15. Fried M, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson IM, et al. TMC 435 in combination with peginterferon and ribavirin in treatment naive HCV genotype 1 patients: Final results of the PILLAR phase IIB study [abstract]. Hepatology. 2011;54(Suppl S1):1429A.
16. Zeuzem S, Berg T, Gane E, et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon ribavirin treatment: Final SVR24 results of the ASPIRE trial [abstract]. J Hepatol. 2012;56(Suppl 2): S1-S2.
17. Sulkowski M, Ceasu E, Asselah T, et al. Silen-C1: sustained virologic response and safety of BI201335 combined with peginterferon alfa-2a and ribavirin in treatment naive patients with chronic genotype 1 infection [abstract]. J Hepatol. 2011;54(Suppl 1):S27.
18. Sulkowski M, Bourliere M, Bronowicki J P, et al. SILEN-C2: Sustained virologic response and safety of BI 201335 combined with peginterferon alfa-2A and ribavirin in chronic HCV genotype 1 patients with non-response to P/R [abstract]. J Hepatol. 2011;54(Suppl 1):S30.
19. Everson G, Cooper C, Hezode C, et al. Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir-boosted danoprevir/PEGIFN alfa-2A/RBV in HCV genotype 1 or 4 patients: DAUPHINE week 12 interim analysis [abstract]. J Hepatol. 2012;56(Suppl 2):S466.
20. Feld JJ, Jacobson I, Jensen DM, Foster GR, Pol S, Tam E, et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir, mericit-abine and ribavirin with or without peginterferon alfa-2a in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study [abstract]. Hepatology. 2012;56(Suppl): 231A-232A.
21. Manns M P, Gane E, Rodriguez-Torres M, et al. Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study. Hepatology. 2012;56(3):884-893.
22. Lawitz E, Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Bhanja S, et al. A phase 2B study of MK 7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment [abstract]. Hepatology. 2011;54: 1434A-1435A.
23. Lawitz E, Poordad F, DeJesus E, et al. ABT-450/ritonavir combined with pegylated interferon alpha-2A and ribavirin after 3 days mono-therapy in genotype 1 HCV-infected treatment-naive subjects: 12 weeks sustained virologic response and safety results [abstract]. J Hepatol. 2012;56(Suppl 2):S470.
24. Poordad F, Lalezari J, Lawitz E, Van Vlierberghe H, Shiffman ML, et al. Continued high virologic response rates with ACH-1625 daily dosing plus pegIFN-alpha-2A in a 28 days and 12 week phase 2a trial [abstract]. J Hepatol. 2012;56(Suppl 2):S455.
25. Bronowicki J-P, Pol S, Thuluvath P, et al. Asunaprevir, an NS3 protease inhibitor in combination with peginterferon and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection [abstract]. J Hepatol. 2012;56(Suppl 2):S431-S432.
26. Lok AS, Gardiner D F, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3): 216-224.
27. Moreno C, Berg T, Tanwandee T, et al. A phase IIA, open label study to assess the antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6. Hepatology. 2010;52(Suppl):749A-750A.
28. Hezode C, Shiffman ML, Cooper C, et al. Ritonavir-boosted danoprevir plus peginterferon alfa-2a/ribavirin demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment-naive patients with genotype 4 infection in the DAUPHINE study [abstract]. Hepatology. 2012;56(Suppl):557A.
29. Brainard DM, Petry A, Van Dyck K, et al. Safety and antiviral activity of MK-5172 a novel HCV NS3/4A protease inhibitors with potent activity against known resistance mutants in genotype 1 and 3 HCV-infected patients [abstract]. Hepatolog y. 2010;52(Suppl):706A-707A.
30. Bourliere M, Khaloun A, Wartelle-Bladou C, et al. Chronic hepatitis C: treatments of the future. Clin Res Hepatol Gastroenterol. 2011; 35 Suppl 2:S84-S95.
31. Membreno FE, Lawitz EJ. The HCV NS5B nucleoside and non-nucleoside inhibitors. Clin Liver Dis. 2011;15(3):611-626.
32. Wedemeyer H, Jensen D, Herring R Jr, et al. Effcacy and safety of mericitabine in combination with PEG-IFN alfa-2A/RBV in G1/4 treatment naive HCV patients: Final analysis from the PROPEL study [abstract]. J Hepatol. 2012;56(Suppl 2):S481-S482.
33. Pockros P, Jensen D, Tsai N, et al. SVR-12 among G1/4 treatment-naive patients receiving mericitabine in combination with PEG-IFN alfa-2A/ RBV: interim analysis from the JUMP-C study [abstract]. J Hepatol. 2012;56(Suppl 2):S477-S478.
34. Gane EJ, Rodriguez-Torres M, Nelson DE, et al. Sustained virologic response following RG7128 1500 mg BID/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non responders [abstract]. J Hepatol. 2010;52(Suppl 1):S16.
35. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1): 34-44.
36. Gane EJ, Stedman CA, Hyland RH, et al. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2 and 3: The ELECTRON trial. Hepatology. 2012;56(Suppl):306A.
37. Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus PEGIFN/RBV in a phase 2B trial: Rapid virologic suppression in treatment-naive patients with HCV GT2/GT3 [abstract]. J Hepatol. 2011;54(Suppl 1):S28.
38. Lawitz E, Gane E, Stedman C, et al. PSI-7977 PROTON and ELECTRON: 100% concordance of SV4 with SVR24 in HCV GT1, GT2 and GT3 [abstract]. J Hepatol. 2012;56(Suppl 2):S4.
39. Hassanein T, Lawitz E, Crespo I, et al. Once daily sofosbuvir (GS-7977) plus PEG/RBV: high early response rates are maintained during post-treatment follow-up in treatment naive patients with HCV genotype 1, 4 and 6 infection in the ATOMIC study [abstract]. Hepatology. 2012;56(Suppl):307A.
40. Larrey D, Lohse AW, de Ledinghen V, et al. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol. 2012;57(1):39-46.
41. Jacobson I, Pockros PJ, Lalezari J, et al. Virologic response rates following 4 weeks of flibuvir in combination with pegylated interferon alfa-2A and ribavirin in chronically-infected HCV genotype-1 patients [abstract]. J Hepatol. 2010;52(Suppl 1):S465.
42. Rodriguez-Torres M, Lawitz E, Conway B, et al. Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment-naive genotype 1 HCV infected patients [abstract]. J Hepatol. 2010;52(Suppl 1):S14.
43. Lawitz E, Rodriguez-Torres M, Rustgi VK, et al. Safety and antiviral activity of ANA 598 in combination with pegylated interferon alfa-2A plus ribavirin in treatment-naive genotype 1 chronic HCV patients [abstract]. Hepatolog y. 2010;52(Suppl):334A-335A.
44. Poordad F, Lawitz E, DeJesus E, et al. ABT-072 or ABT-333 combined with pegylated interferon and ribavirin after 3 days monotherapy in HCV genotype 1 infected treatment-naive subjects: 12 week sustained virologic response and safety results [abstract]. J Hepatol. 2012; 56(Suppl 2):S478.
45. Lawitz E, Jacobson I, Godofsky E, et al. A phase 2B trial comparing 24 to 48 weeks treatment with tegobuvir (GS-9190)/PEG/RBV to 48 weeks treatment with PEG/RBV for chronic genotype 1 HCV infection [abstract]. J Hepatol. 2011;54(Suppl 1):S181.
46. Suk-Fong Lok A. HCV NS5A inhibitors in development. Clin Liver Dis. 2013;17:111-121.
47. Hezode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment naive HCV genotype 1or 4 subjects: phase 2b COMMAND-1 SVR12 results [abstract]. Hepatology. 2012; 56(Suppl):553A.
48. Ratziu V, Gadano A, Pol S, et al. Triple therapy with daclatasvir, peginterferon alfa-2a and ribavirin in HCV infected prior null and partial responders: 12 weeks results of phase 2b COMMAND-2 trial [abstract]. J Hepatol. 2012;56(Suppl 2):S478-S479.
49. Dore GJ, Lawitz E, Hezode C, et al. Twelve or 16 week treatment with daclatasvir combined with peginterferon alfa and ribavirin for hepatitis C virus genotype 2 or 3 infection: COMMAND GT2/3 study [abstract]. Hepatology. 2012;56(Suppl):558A-559A.
50. Lok AS, Gardiner D F, Hezode C, et al. Sustained virologic response in chronic HCV genotype 1-infected null responders with the combination of daclatasvir and asunaprevir with or without peginter-feron alfa-2a/ribavirin [abstract]. Hepatology. 2012;56(Suppl): 230A.
51. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. High rate of sustained virologic response with all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (Nucleotide NS5B inhibitor) with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1,2 or 3 [abstract]. Hepatology. 2012; 56(Suppl):LB-2.
52. Sullivan GJ, Rodriguez-Torres M, Lawitz E, et al. ABT-267 combined with pegylated interferon alpha-2A and ribavirin in genotype 1 HCV-infected treatment-naive subject: 12 week antiviral and safety analysis [abstract]. J Hepatol. 2012;56(Suppl 2):S480.
53. Sulkowski MS, Rodriguez-Torres M, Lawitz E, et al. High sustained virologic response rate in treatment-naive HCV genotype 1A and 1B patients treated for 12 weeks with an interferon-free all-oral quad regimen: interim results [abstract]. J Hepatol. 2012;56(Suppl 2):S560.
54. Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodefciency virus. Hepatology. 2008;47(3): 817-826.
55. Membreno FE, Espinales JC, Lawitz EJ. Cyclophilin inhibitors for hepatitis C therapy. Clin Liver Dis. 2013;17:129-139.
56. Alberti A, Chuang WL, Flisiak R, et al. Alisporivir plus peginterferon/ ribavirin in HCV genotype 1 treatment-experienced patients achieves primary endpoint with superior effcacy at treatment week 12 compared to retreatment with PR [abstract]. J Hepatol. 2012;56(Suppl 2): S553-S554.
57. Pawlostky J-M, Sarin SK, Foster G, et al. Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2or GT3 patients: SVR12 results from VITAL-1 phase 2b study [abstract]. J Hepatol. 2012;56(Suppl 2):S553.
58. Wedemeyer H, Janczewska E, Wlodzimierz M, et al. Significant improvement of complete EVR in HCVAC phase II clinical trial when adding TG4040 therapeutic vaccine to PEGIFN alfa-2A and ribavirin [abstract]. J Hepatol. 2012;56(Suppl 2):S552.
59. Biermer M, Schlosser B, Fulop B, et al. High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. J Viral Hepat. 2012;19(8): 547-553.
60. Muir AJ, Hillson JA, Gray TE, et al. Peginterferon Lambda-1a compared to peginterferon alpha-2a in treatment-naive patients with HCV genotype 1 or 4. SVR24 from EMERGE phase 2b [abstract]. Hepatol-ogy. 2012;56(Suppl):299A.
61. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376(9751):1467-1475.
62. Gane EJ, Pockros P, Zeuzem S, et al. Interferon-free treatment with a combination of mericitabine and danoprevir/R with or without riba-virin in treatment-naive HCV genotype 1 infected patients [abstract]. J Hepatol. 2012;56(Suppl 2):S555-S556.
63. Zeuzem S, Asselah T, Angus P, et al. Effcacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology. 2011;141(6):2047-2055.
64. Zeuzem S, Soriano V, Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127 +/- ribavirin in treatment naive patients with chronic genotype 1 HCV infection; interim results of SOUND-C2 [abstract]. J Hepatol. 2012; 56(Suppl 2):S45.
65. Zeuzem S, Soriano V, Asselah T, et al. Interferon-free combination treatment with HCV NS3/NS4 protease inhibitor BI201335 and the non nucleoside NS5B inhibitor BI 207127 with or without ribavirin: Final results of SOUND-C2 and predictors of response [abstract]. Hepatology. 2012;56(Suppl):308A-309A.
66. Di Bisceglie AM, Nelson DR, Gane E, et al. VX-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment naive patients with chronic hepatitis C: ZENITH study interim results [abstract]. J Hepatol. 2011;54(Suppl 1):S540.
67. Jacobson I, Sulkowski MS, Gane EJ, et al. VX-222, telaprevir and riba-virin in treatment-naive patients with genotype 1 chronic hepatitis C: results of the ZENITH study interferon-free regimen [abstract]. Hepa-tolog y. 2012;56(Suppl):308A.
68. Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment naive genotype 1 HCV subjects [abstract]. Hepatology. 2010;52(Suppl):400A.
69. Poordad F, Lawitz E, Kowdley K V, et al. 12 week interferon-free regimen of ABT-450/R + ABT-333 + ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype 1 infected subjects and 47% of previous non-responders [abstract]. J Hepatol. 2012;56(Suppl 2): S549-S550.
70. Kowdley K V, Lawitz E, Poordad F, et al. A 12 week interferon-free treatment regimen with ABT-450/R, ABT-267, ABT-333 and ribavirin achieves a SVR12 rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection Hepatology. 2012;56(Suppl):LB-1.
71. Lawitz E, Poordad F, Kowdley K V, et al. A 12 week interferon-free regimen of ABT-450/R, ABT-072 and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naive HCV IL28B-CC genotype1 infected subjects [abstract]. J Hepatol. 2012;56(Suppl 2):S7.
72. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstruc-tural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55(3):742-748.
73. Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with the all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (nucleotide NS5B inhibitor +/- ribavirin in treatment-naive patients with chronic HCV GT1,2, or 3 [abstract]. J Hepatol. 2012;56(Suppl 2):S560.
74. Everson GT, Sims KD, Rodriguez-Torres M, et al. An interferon-free, ribavirin-free 12-week regimen of daclatasvir, asunaprevir and BMS-791325 yielded SVR4 of 94% in treatment-naive patients with genotype 1 chronic hepatitis C virus infection [abstract]. Hepatology. 2012;56(Suppl):LB-3.
75. Nelson DR, Gane EJ, Jacobson IM, et al. VX222/Telaprevir in combination with peginterferon alfa-2A and ribavirin in treatment-naive genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interil analysis [abstract]. Hepatolog y. 2011;54(Suppl):1435A.
76. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013. [Epub ahead of print].
77. Marcellin P, Cheinquer H, Curescu M, et al. Worldwide experience treating chronic hepatitis C with peginterferon alfa/ribavirin: Final results from 7163 naive mono-infected patients enrolled in the large multinational PROPHESYS cohort study. Hepatology. 2011; 54(Suppl):824A.
78. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245-264.
79. Foster GR, Hezode C, Bronowicki J P, et al. Telaprevir alone or with peginter-feron and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology. 2011;141(3):881-889. e1.
80. Benhamou Y, Moussalli J, Ratziu V, et al. Activity of telaprevir or in combination with peginterferon alfa-2a and ribavirin in treatment naive genotype 4 hepatitis C patients. Final results of study C210. [abstract]. Hepatology. 2010;52(Suppl):719A-720A.
81. Silva MO, Kasserra C, Gupta A, Treitel M, Hughes E, O'Mara E. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3 A PASL Feb 17-20, 2011. 2011;10:13-66.
82. Summa V, Ludmerer S W, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012;56(8):4161-4167.
83. Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology. 2006;43(4):761-770.
84. Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 mono-therapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012;56(6):1247-1253.
85. Pockros P, Jensen D, Tsai N, et al. SVR12 among G1/4 treatement naive patients receiving mericitabine in combination with PEG-IFN alfa-2a/ ribavirin; Interim analysis from the JUMP-C study [abstract]. J Hepatol. 2012;56(Suppl 2):S477-S478.
86. Kowdley K V, Lawitz E, Crespo I, et al. ATOMIC: 97% RVR for PSI-7977 + PEG/RBV × 12 week regimen in HCV GT1: an end to response-guided therapy [abstract]? J Hepatol. 2012;56(Suppl 2):S1.
87. Hezode C, Dorival C, Zoulim F, et al. Safety and effcacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin in 455 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting [abstract]. Hepatolog y. 2012;56(Suppl):217A.
88. Coilly A, Roche B, Botta-Fridlund D, et al. Effcacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: A frst multicentric experience [abstract]. J Hepatol. 2012; 56(Suppl 2):S21.
89. Bourliere M, Wendt A, Fontaine H, Hezode C, Pol S, Bronowicki J P. How to optimize HCV therapy in genotype 1 patients with cirrhosis. Liver Int. 2013;33(Suppl 1):46-55.
90. Lawitz E, Rodriguez-Torres M, Cornpropst MT, et al. The effect of hepatic impairment on the pharmacokinetics and antiviral activity of PSI-7977 in hepatitis C infected subjects treated for seven days [abstract]. J Hepatol. 2012;56(Suppl 2):S445-S446.
91. Soriano V, Gane EJ, Angus P W, et al. Effcacy and safety of the interferon-free combination of BI 201335 + BI 207127 with or without ribavirin in treatment-naive patients with HCV genotype 1 infection and compensated liver cirrhosis: results from the SOUND-C2 study [abstract]. Hepatology. 2012;56(Suppl 1):234A.
92. Marcellin P, Manns M, Janczewska E, et al. 12 weeks response- guided treatment with the NS5A inhibitor, GS-5885, the NS3 protease inhibitor, GS-9451, plus pegylated interferon and ribavirin in treatment naive genotype 1 hepatitis C infected patients. J Hepatol. 2013;58(2):S355.
93. Thompson A, Han S, Shiffman M, et al. (2013) GS-5885 + GS- 9451 + PEGinterferon and ribavirin for six or twelve weeks achieves high SVR12 rates in treatment naive genotype1 IL28B CC patients. J Hepatol. 2013;58(2):S29.
94. Everson G, Di Bisceglie A, Vierling J, et al. (2013) Combination of the NS5A inhibitor GS-5885, the NS3 protease inhibitor GS-9451 and pegylated interferon plus riba- virin in treatment experienced patients with genotype 1 hepatitis C infection. J Hepatol. 58(2):S6.
95. Lawitz E, Ghalib R, Rodriguez-Torres M. SVR4 results of a once daily regimen of simeprevir (TMC-435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV GT-1 null respon- ders. DDW Orlando May 18-21, 2013. Gastroenterology. Abstract Sa 2013;144(1):374-375.
96. Manns M, Marcellin P, Poordad F, De Araujo E, Buti M, Horsmans Y, et al. Simeprevir (TMC 435) with PEGinterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treat-ment-naive patients: results from Quest -2. A phase III trial. J Hepatol. 2013;58(Suppl 1): S568.
97. Jacobson I, Dore G, Foster G, Fried M, Radu M, Rafalskiy V, et al. Simeprevir (TMC 435) with PEGinterferon/ribavirin for chronic HCV geno- type-1 infection in treatment naive patients: results from Quest-1, a phase III trial. J Hepatol. 2013;58(Suppl 1):S574.98.
98. Zeuzem S, Berg T, Gane E et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon ribavirin treatment: final SVR24 results of the ASPIRE trial. J Hepatol. 2012;56(Suppl 2):S1.
99. Kowdley K, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treat- ment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381:2100-2107.
100. Lawitz E, Gane E, Stedman C, et al. PSI-7977 proton and electron: 100% concordance of SV4 with SVR24 in HCV GT1, GT2 and GT3. J Hepatol. 2012;56(Suppl 2):S4.
101. Lawitz E, Lalezari J, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with geno- types 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis13. 2013:401-408.
102. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013. 368:1878-1887.
103. Rodriguez-Torres M, Lawitz E, Kowdley K, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol. 2013:58:663-668.
104. Gane E, Stedman C, Hyland R, et al. Nucleotide polymerase inhibitor sofosbuvir plus riba- virin for hepatitis C. N Engl J Med. 2013;368: 34-44.
105. Gane E, Stedman C, Hyland R, et al. All-oral sofosbuvir- based 12 week regimen for the treatment of chronic HCV infection: the Electron study. J Hepatol. 2013;58(Suppl. 1):S6-S7.
106. Lawitz, E, Ghalib R, Rodriguez-Torres M. SVR4 results of a once daily regimen of simeprevir (TMC-435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV GT-1 null respon-ders. DDW Orlando. 2013;18-21.
107. Marcellin P, Manns M, Janczewska E, et al. 12 weeks response-guided treatment with the NS5A inhibitor, GS-5885, the NS3 protease inhibitor, GS-9451, plus pegylated interferon and ribavirin in treatment naive genotype 1 hepatitis C infected patients. J Hepatol. 2013;58(Suppl 2): S355.
108. Thompson A, Han S, Shiffman M, et al. GS-5885 {thorn} GS- 9451 {thorn} PEG interferon and ribavirin for six or twelve weeks achieves high SVR12 rates in treatment naive genotype 1 IL28B CC patients. J Hepatol. 2013;58(Suppl 2):S29.
109. Everson G, Di Bisceglie A, Vierling J, et al. Combination of the NS5A inhibitor GS-5885, the NS3 protease inhibitor GS-9451 and pegylated interferon plus riba-virin in treatment experienced patients with genotype 1 hepatitis C infection. J Hepatol. 2013;58(Suppl 2):S6.
110. Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with the all-oral combination of daclatas-vir (NS5A inhibitor) and GS-7977 (nucleotide NS5B inhibitor {thorn}/- ribavirin in treatment-naive patients with chronic HCV GT1,2, or 3. J Hepatol. 2012;56:S560.
111. Sulkowski M, Gardiner D, Rodriguez-Torres M, et al. Sustained virologic response with daclatasvir plus sofosbuvir with or without ribavirin in chronic HCV genotype 1 infected patients who previously failed tel-aprevir or borceprevir. J Hepatol. 2013;58(Suppl 2): S570.